|
13 Sep 2025 |
Shree Cements
|
Consensus Share Price Target
|
29580.00 |
30948.50 |
- |
4.63 |
hold
|
|
|
|
|
01 Nov 2021
|
Shree Cements
|
Axis Direct
|
29580.00
|
30000.00
|
28868.15
(2.47%)
|
|
Hold
|
|
|
Hence we maintain our HOLD rating on the stock. We value the company at 19x of its FY23E EV/EBITDA to arrive at a target price of Rs 30,000/share, implying an upside of 5% from CMP.
|
|
03 Sep 2021
|
Shree Cements
|
Axis Direct
|
29580.00
|
30323.00
|
30440.80
(-2.83%)
|
Target met |
Hold
|
|
|
We value SCL at 19x FY23E EV/EBITDA and assign a HOLD rating to the company.
|
|
10 Aug 2021
|
Shree Cements
|
SMC online
|
29580.00
|
|
26600.40
(11.20%)
|
|
Results Update
|
|
|
Operating profit margin stood at 0.28%, leading to 48.71% rise in operating profit to Rs 1,022.96 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 7.12% to 6.94%. Purchase of finished goods cost rose from 0.16% to 1.27%. Employee...
|
|
10 Aug 2021
|
Shree Cements
|
Axis Direct
|
29580.00
|
29000.00
|
27117.65
(9.08%)
|
Target met |
Hold
|
|
|
we maintain our HOLD rating on the stock with TP of Rs.29000/share implying an upside of 3% from CMP.
|
|
10 Aug 2021
|
Shree Cements
|
Motilal Oswal
|
29580.00
|
28550.00
|
27117.65
(9.08%)
|
Target met |
Neutral
|
|
|
Shree Cement (SRCM)'s 1QFY22 result was in-line, with EBITDA up 45% YoY as higher realization was offset by disappointment on cost, leading to weaker EBITDA/t of INR1,482 (v/s our est. of INR1,552/t). Volume growth at 39% YoY, weighed by lower clinker sales, was also weaker v/s peers. We broadly maintain our FY22E/FY23E estimates and expect a 13%/13% volume/EBITDA CAGR over FY2123E. We maintain Neutral as the valuation (18x FY23E EV/EBITDA) prices in earnings growth....
|
|
10 Aug 2021
|
Shree Cements
|
ICICI Securities Limited
|
29580.00
|
31200.00
|
26547.50
(11.42%)
|
Target met |
Buy
|
|
|
manufactures specialty organic bromine-based chemical compounds as well as specialty inorganic lithium-based chemicals compounds. Neogen has two segments viz. (i) organic chemicals, (ii) inorganic chemicals...
|
|
25 May 2021
|
Shree Cements
|
Geojit BNP Paribas
|
29580.00
|
28810.00
|
27655.10
(6.96%)
|
Target met |
Hold
|
|
|
Shree Cement Limited provides building materials. The company manufactures and sells cement and cement products in India. The company currently operates with a total cement capacity of 44.4mpta of which...
|
|
24 May 2021
|
Shree Cements
|
SMC online
|
29580.00
|
|
27041.45
(9.39%)
|
|
|
|
|
Performance for the quarter ended March 2021 Total consolidated income from operation inclined 23% to Rs 4,204.88 crore for the fourth quarter ended March 2021. OPM decreased by 150 bps to 29.4%. The decrement in OPM was due to gain in freight & forwarding cost by 220 bps to 23.4%, employee costs by 70 bps to 6.6%, other expenses by 60 bps to 15.4%, and raw material costs by 40 bps to 7.2% as percentage to sales and net of stock adjustments, partially offset by decline in power & fuel cost by 340 bps to 17%. As a result, the OP growth trimmed to 17% at Rs 1,237.78 crore....
|
|
24 May 2021
|
Shree Cements
|
IDBI Capital
|
29580.00
|
25610.00
|
27655.10
(6.96%)
|
Target met |
Sell
|
|
|
Shree Cement (SRCM) Q4FY21 EBITDA was in-line with our and consensus estimate. SRCM volume increase at +19% YoY was strong. Post the result we have increased EBITDA estimate for FY22E and FY23E by 6% and 11%. This factors higher ASP (as Q4FY21 realization is up 4% QoQ), lower opex/t versus earlier estimate for FY22E/23E. We continue to value SCRM at 18x FY23E EV/EBITDA and revised TP is Rs25,610 (earlier Rs22,517). But given there is a down downside of 7% to our fair value, we lower stock rating to reduce. SRCM valuation premium to UTCEM has narrowed to 35% (from the highs of 80%) vs. historical average of 45%. But expectation of weak 1HFY22 is weighing...
|
|
24 May 2021
|
Shree Cements
|
Axis Direct
|
29580.00
|
29000.00
|
26909.35
(9.92%)
|
Target met |
Hold
|
|
|
We value the company at 19x of its FY23E EV/EBITDA, to arrive at a target price of Rs.29000/share, implying an upside of 5% from CMP.
|